Biogen Idec (BIIB) Affirms Receipt of FDA Approval for TECFIDERA as MS Treatment
Go back to Biogen Idec (BIIB) Affirms Receipt of FDA Approval for TECFIDERA as MS Treatment| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 216.78 +2.43 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $214.35 | 52 Week High | $333.65 | |||
| Open | $217.76 | 52 Week Low | $223.02 | |||
| Day High | $219.12 | P/E | 27.76 | |||
| Day Low | $215.00 | EPS | $7.81 | |||
| Volume | 722,348 | |||||
